ArticleJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2022
RANKL Blockade Reduces Cachexia and Bone Loss Induced by Non-Metastatic Ovarian Cancer in Mice.
Article in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Beyond bone effects: the role of denosumab in muscle Health - A systematic review.Aging clinical and experimental research · 2026Pooled it
- Age-dependent musculoskeletal changes during mechanical unloading with bisphosphonate treatment.Bone · 2026Article
- From Molecular Pathways to Artificial Intelligence: Advancing the Understanding and Management of Osteosarcopenia.International journal of molecular sciences · 2026Review
- Bone Loss, Osteoporosis, and Skeletal Fragility: Hidden Consequences of Cancer Cachexia.Cells · 2026Review
- Article
- Sex specific effects of irisin on the skeleton.Bone research · 2026Review
- Prevalence of ovarian cancer cachexia in patients undergoing cytoreductive surgery at the University of Colorado between 2014-2024.Journal of ovarian research · 2026Article
- Cancer cachexia: molecular basis and therapeutic advances.Signal transduction and targeted therapy · 2026Review
- MLM3 and MLM5 head and neck cancer models promote age-dependent musculoskeletal deterioration in mice.Scientific reports · 2025Article
- Osteoporosis and Fracture Risk in Ovarian Cancer: Beyond the Oncologic Burden.Diagnostics (Basel, Switzerland) · 2025Review
- Physical Activity, Exerkines, and Their Role in Cancer Cachexia.International journal of molecular sciences · 2025Review
- Aging: A struggle for beneficial to overcome negative factors made by muscle and bone.Mechanisms of ageing and development · 2025Review
- Serum bone metabolism biomarkers in predicting tumor bone metastasis risk and their association with cancer pain: a retrospective study.Frontiers in pain research (Lausanne, Switzerland) · 2025Article
- Extra-osseous Roles of the RANK-RANKL-OPG Axis with a Focus on Skeletal Muscle.Current osteoporosis reports · 2024Review
- The Impact of Non-bone Metastatic Cancer on Musculoskeletal Health.Current osteoporosis reports · 2024Review
- Article
- Deletion of FNDC5/Irisin modifies murine osteocyte function in a sex-specific manner.bioRxiv : the preprint server for biology · 2024Article
- Mechanisms of Ovarian Cancer-Associated Cachexia.Endocrinology · 2023Review
- Role of growth differentiation factor 15 in cancer cachexia (Review).Oncology letters · 2023Review
- Association of malignant ascites with systemic inflammation and muscle loss after treatment in advanced-stage ovarian cancer.Journal of cachexia, sarcopenia and muscle · 2023Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Tumor- and bone-derived soluble factors have been proposed to participate in the alterations of skeletal muscle size and function in cachexia. We previously showed that mice bearing ovarian cancer (OvCa) exhibit cachexia associated with marked bone loss, whereas bone-targeting agents, such as bisphosphonates, are able to preserve muscle mass in animals exposed to anticancer drugs. De-identified CT images and plasma samples from female patients affected with OvCa were used for body composition assessment and quantification of circulating cross-linked C-telopeptide type I (CTX-I) and receptor activator of NF-kB ligand (RANKL), respectively. Female mice bearing ES-2 tumors were used to characterize cancer- and RANKL-associated effects on muscle and bone. Murine C2C12 and human HSMM myotube cultures were used to determine the OvCa- and RANKL-dependent effects on myofiber size. To the extent of isolating new regulators of bone and muscle in cachexia, here we demonstrate that subjects affected with OvCa display evidence of cachexia and increased bone turnover. Similarly, mice carrying OvCa present high RANKL levels. By using in vitro and in vivo experimental models, we found that elevated circulating RANKL is sufficient to cause skeletal muscle atrophy and bone resorption, whereas bone preservation by means of antiresorptive and anti-RANKL treatments concurrently benefit muscle mass and function in cancer cachexia. Altogether, our data contribute to identifying RANKL as a novel therapeutic target for the treatment of musculoskeletal complications associated with RANKL-expressing non-metastatic cancers. © 2021 American Society for Bone and Mineral Research (ASBMR).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.